Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide

Paul J. Hesketh, David R. Gandara, Ann M. Hesketh, Anna Facada, Edith A. Perez, Lauri M. Webber, Lorene A. Martin, Michael B. Cramer, William F. Hahne

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Selective 5-HT3 antagonists have proven to be safe and effective for the prevention of chemotherapy-induced nausea and vomiting. Dolasetron is a new highly selective addition to this class of antiemetics that has been shown to have significant antiemetic activity in patients receiving cisplatin-containing regimens. This pilot study was designed to evaluate the antiemetic efficacy of dolasetron in cancer patients receiving doxorubicin and/or cyclophosphamide. This study used an open-label, non-randomized design to evaluate the efficacy and safety of intravenous dolasetron in the prevention of emesis in patients receiving doxorubicin (25-75 mg/m2) and/or cyclophosphamide (400-1200 mg/m2). Sixty-nine patients received a single, intravenous dose of dolasetron over 15-20 min beginning 30 min prior to the start of chemotherapy. Dose levels of dolasetron studied were: 0.3, 0.6, 1.2. 1.8 and 2.4 mg/kg. Patients were monitored for emesis, nausea and adverse events for 24 h after the start of chemotherapy. Overall, 61% of patients experienced complete control of emesis. No significant trend towards increased antiemetic efficacy (P=0.076) or nausea control with increasing dolasetron dose was noted, although the power to detect significant differences was limited by the small number of patients on the 0.3-mg/kg and 2.4-mg/kg dose levels. Age, gender, and type of chemotherapy were significant predictors of complete antiemetic control. Adverse events were generally mild and included headache, chills, lightheadedness, fever, diarrhea, dizziness, and asymptomatic prolongation of ECG intervals. Intravenous dolasetron is safe and effective in the prevention of emesis induced by doxorubicin and/or cyclophosphamide.

Original languageEnglish (US)
Pages (from-to)141-146
Number of pages6
JournalSupportive Care in Cancer
Volume4
Issue number2
StatePublished - Mar 1996
Externally publishedYes

Fingerprint

Antiemetics
Doxorubicin
Cyclophosphamide
Drug Therapy
Vomiting
Nausea
Dizziness
Serotonin 5-HT3 Receptor Antagonists
Chills
dolasetron
Cisplatin
Headache
Diarrhea
Electrocardiography
Fever
Safety
Neoplasms

Keywords

  • Antiemetic
  • Dolasetron
  • Dose-ranging trial
  • Emesis
  • Nausea

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Hesketh, P. J., Gandara, D. R., Hesketh, A. M., Facada, A., Perez, E. A., Webber, L. M., ... Hahne, W. F. (1996). Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Supportive Care in Cancer, 4(2), 141-146.

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. / Hesketh, Paul J.; Gandara, David R.; Hesketh, Ann M.; Facada, Anna; Perez, Edith A.; Webber, Lauri M.; Martin, Lorene A.; Cramer, Michael B.; Hahne, William F.

In: Supportive Care in Cancer, Vol. 4, No. 2, 03.1996, p. 141-146.

Research output: Contribution to journalArticle

Hesketh, PJ, Gandara, DR, Hesketh, AM, Facada, A, Perez, EA, Webber, LM, Martin, LA, Cramer, MB & Hahne, WF 1996, 'Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide', Supportive Care in Cancer, vol. 4, no. 2, pp. 141-146.
Hesketh, Paul J. ; Gandara, David R. ; Hesketh, Ann M. ; Facada, Anna ; Perez, Edith A. ; Webber, Lauri M. ; Martin, Lorene A. ; Cramer, Michael B. ; Hahne, William F. / Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. In: Supportive Care in Cancer. 1996 ; Vol. 4, No. 2. pp. 141-146.
@article{97fa24fef2664879ba7697564835a775,
title = "Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide",
abstract = "Selective 5-HT3 antagonists have proven to be safe and effective for the prevention of chemotherapy-induced nausea and vomiting. Dolasetron is a new highly selective addition to this class of antiemetics that has been shown to have significant antiemetic activity in patients receiving cisplatin-containing regimens. This pilot study was designed to evaluate the antiemetic efficacy of dolasetron in cancer patients receiving doxorubicin and/or cyclophosphamide. This study used an open-label, non-randomized design to evaluate the efficacy and safety of intravenous dolasetron in the prevention of emesis in patients receiving doxorubicin (25-75 mg/m2) and/or cyclophosphamide (400-1200 mg/m2). Sixty-nine patients received a single, intravenous dose of dolasetron over 15-20 min beginning 30 min prior to the start of chemotherapy. Dose levels of dolasetron studied were: 0.3, 0.6, 1.2. 1.8 and 2.4 mg/kg. Patients were monitored for emesis, nausea and adverse events for 24 h after the start of chemotherapy. Overall, 61{\%} of patients experienced complete control of emesis. No significant trend towards increased antiemetic efficacy (P=0.076) or nausea control with increasing dolasetron dose was noted, although the power to detect significant differences was limited by the small number of patients on the 0.3-mg/kg and 2.4-mg/kg dose levels. Age, gender, and type of chemotherapy were significant predictors of complete antiemetic control. Adverse events were generally mild and included headache, chills, lightheadedness, fever, diarrhea, dizziness, and asymptomatic prolongation of ECG intervals. Intravenous dolasetron is safe and effective in the prevention of emesis induced by doxorubicin and/or cyclophosphamide.",
keywords = "Antiemetic, Dolasetron, Dose-ranging trial, Emesis, Nausea",
author = "Hesketh, {Paul J.} and Gandara, {David R.} and Hesketh, {Ann M.} and Anna Facada and Perez, {Edith A.} and Webber, {Lauri M.} and Martin, {Lorene A.} and Cramer, {Michael B.} and Hahne, {William F.}",
year = "1996",
month = "3",
language = "English (US)",
volume = "4",
pages = "141--146",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide

AU - Hesketh, Paul J.

AU - Gandara, David R.

AU - Hesketh, Ann M.

AU - Facada, Anna

AU - Perez, Edith A.

AU - Webber, Lauri M.

AU - Martin, Lorene A.

AU - Cramer, Michael B.

AU - Hahne, William F.

PY - 1996/3

Y1 - 1996/3

N2 - Selective 5-HT3 antagonists have proven to be safe and effective for the prevention of chemotherapy-induced nausea and vomiting. Dolasetron is a new highly selective addition to this class of antiemetics that has been shown to have significant antiemetic activity in patients receiving cisplatin-containing regimens. This pilot study was designed to evaluate the antiemetic efficacy of dolasetron in cancer patients receiving doxorubicin and/or cyclophosphamide. This study used an open-label, non-randomized design to evaluate the efficacy and safety of intravenous dolasetron in the prevention of emesis in patients receiving doxorubicin (25-75 mg/m2) and/or cyclophosphamide (400-1200 mg/m2). Sixty-nine patients received a single, intravenous dose of dolasetron over 15-20 min beginning 30 min prior to the start of chemotherapy. Dose levels of dolasetron studied were: 0.3, 0.6, 1.2. 1.8 and 2.4 mg/kg. Patients were monitored for emesis, nausea and adverse events for 24 h after the start of chemotherapy. Overall, 61% of patients experienced complete control of emesis. No significant trend towards increased antiemetic efficacy (P=0.076) or nausea control with increasing dolasetron dose was noted, although the power to detect significant differences was limited by the small number of patients on the 0.3-mg/kg and 2.4-mg/kg dose levels. Age, gender, and type of chemotherapy were significant predictors of complete antiemetic control. Adverse events were generally mild and included headache, chills, lightheadedness, fever, diarrhea, dizziness, and asymptomatic prolongation of ECG intervals. Intravenous dolasetron is safe and effective in the prevention of emesis induced by doxorubicin and/or cyclophosphamide.

AB - Selective 5-HT3 antagonists have proven to be safe and effective for the prevention of chemotherapy-induced nausea and vomiting. Dolasetron is a new highly selective addition to this class of antiemetics that has been shown to have significant antiemetic activity in patients receiving cisplatin-containing regimens. This pilot study was designed to evaluate the antiemetic efficacy of dolasetron in cancer patients receiving doxorubicin and/or cyclophosphamide. This study used an open-label, non-randomized design to evaluate the efficacy and safety of intravenous dolasetron in the prevention of emesis in patients receiving doxorubicin (25-75 mg/m2) and/or cyclophosphamide (400-1200 mg/m2). Sixty-nine patients received a single, intravenous dose of dolasetron over 15-20 min beginning 30 min prior to the start of chemotherapy. Dose levels of dolasetron studied were: 0.3, 0.6, 1.2. 1.8 and 2.4 mg/kg. Patients were monitored for emesis, nausea and adverse events for 24 h after the start of chemotherapy. Overall, 61% of patients experienced complete control of emesis. No significant trend towards increased antiemetic efficacy (P=0.076) or nausea control with increasing dolasetron dose was noted, although the power to detect significant differences was limited by the small number of patients on the 0.3-mg/kg and 2.4-mg/kg dose levels. Age, gender, and type of chemotherapy were significant predictors of complete antiemetic control. Adverse events were generally mild and included headache, chills, lightheadedness, fever, diarrhea, dizziness, and asymptomatic prolongation of ECG intervals. Intravenous dolasetron is safe and effective in the prevention of emesis induced by doxorubicin and/or cyclophosphamide.

KW - Antiemetic

KW - Dolasetron

KW - Dose-ranging trial

KW - Emesis

KW - Nausea

UR - http://www.scopus.com/inward/record.url?scp=0030097739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030097739&partnerID=8YFLogxK

M3 - Article

C2 - 8673351

AN - SCOPUS:0030097739

VL - 4

SP - 141

EP - 146

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -